The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetes mellitus people have a higher incidence of cardiovascular disease, and the results of cardiovascular events are worse. Heart failure and diabetes both have a worse prognosis, with a 1.5-2 times increased risk of death. Data from the literature have shown that MET lowers mortality by 14-35% in this patient population, which represents one-third of all HF patients with no increases in lactic acidosis incidence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sara ElAdawy
• Collaborator: Cairo University
• Treatments: Metformin

Criteria

Inclusion Criteria:

• - Inclusion criteria:

• Age of 40 years to 74 years.

• HFpEF (≥ 50%)

• Written informed consent of the subject to participate in the study.

• New York Heart Association functional class II-IV.

• Body mass index ≥ 30 Kg/m2

Exclusion Criteria:

• - Exclusion criteria:

• Patients with heart failure with reduced ejection fraction (< 40%)

• Age less than 40 and more than 74

• New York Heart Association functional class I

• Body mass index < 30 Kg/m2

• Diabetic patients or prior metformin user

• Renal impairment

• Known allergy to metformin

• End- stage liver disease

• Cancer

• Pregnancy or lactation